Key Takeaways
- • AbbVie has agreed to acquire Apogee Therapeutics at a total equity value of approximately $10.9 billion, marking a significant expansion into inflammatory and immunological disease therapies.
- • Paul Weiss Rifkind Wharton & Garrison LLP and Kirkland & Ellis LLP are co-advising on the transaction, underscoring the deal's complexity and strategic importance.
- • Apogee Therapeutics specializes in developing therapies for inflammatory and immunological diseases, representing a strategic therapeutic area addition to AbbVie's portfolio.
- • The transaction was announced on June 22, 2026, signaling continued M&A activity in the biopharmaceutical sector despite broader market conditions.
Summary
AbbVie announced on Monday, June 22, 2026, that it has agreed to acquire Apogee Therapeutics in an all-equity transaction valued at approximately $10.9 billion. The deal represents AbbVie's latest strategic move to strengthen its pipeline and expand its presence in inflammatory and immunological disease therapeutics, therapeutic areas critical to the company's long-term growth strategy.
Apogee Therapeutics, the acquisition target, operates as a specialized biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases. The company's therapeutic focus aligns with established market demand and represents a strategic addition to AbbVie's existing portfolio in these disease areas.
The transaction is being guided by two major law firms: Paul Weiss Rifkind Wharton & Garrison LLP and Kirkland & Ellis LLP, both serving as co-advisors. The involvement of these prominent deal counsel reflects the transaction's scale and the sophistication required to execute a near-$11 billion equity acquisition in the biopharmaceutical sector.
This acquisition continues a pattern of consolidation activity within the pharmaceutical and biotech industries, as larger companies seek to bolster their pipelines and acquire specialized therapeutic capabilities. The deal is expected to enhance AbbVie's competitive positioning in inflammatory and immunological disease treatment markets, historically lucrative segments within the broader biopharmaceutical space.
Apogee Therapeutics, the acquisition target, operates as a specialized biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases. The company's therapeutic focus aligns with established market demand and represents a strategic addition to AbbVie's existing portfolio in these disease areas.
The transaction is being guided by two major law firms: Paul Weiss Rifkind Wharton & Garrison LLP and Kirkland & Ellis LLP, both serving as co-advisors. The involvement of these prominent deal counsel reflects the transaction's scale and the sophistication required to execute a near-$11 billion equity acquisition in the biopharmaceutical sector.
This acquisition continues a pattern of consolidation activity within the pharmaceutical and biotech industries, as larger companies seek to bolster their pipelines and acquire specialized therapeutic capabilities. The deal is expected to enhance AbbVie's competitive positioning in inflammatory and immunological disease treatment markets, historically lucrative segments within the broader biopharmaceutical space.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.